The California Workers' Compensation Institute on Wednesday reported that meloxicam has become the largest source of anti-inflammatory drug spending, with its share of payments jumping from less than 2% in 2020 to 30.8% last year, largely because of a small number of high-cost formulations.
CWCI also reports that the committee that advised the Division of Workers' Compensation on changes to the prescription drug formulary in 2020 and 2021 considered requiring prospective utilization review for the high-cost, novel formulations of the drug that appear to be driving the recent...
Comments